Linifanib-分析及2013年∼2020年的市場預測 是由出版商GlobalData在2011年07月所出版的。
這份英文市場調查報告書包含Pages: 28 價格從美金2000起跳。
全球肝癌市場在2010年達到4億美金的規模，今後預計也將以穩定的步調成長。全球肝癌市場，預測在今後將以10∼15%的年複合成長率繼續增加。
本報告提供肝癌市場概要彙整，以其為目標的治療藥物Linifanib相關資料，彙整作用機制，風險-優點評比，銷售額預測等分析，為您概述為以下內容。
第1章 目錄
第2章 簡介
第3章 肝癌:市場特性
- 肝癌市場
- 肝癌市場預測及年複合成長率
- 肝癌市場推動因素
第4章 肝癌的TWN分期
第5章 Linifanib
- 簡介
- 作用機制
- 臨床研究
- Linifanib的適應症
- Linifanib的銷售額影響因素
- 藥物的風險-優點評比
- 競爭激烈
- 銷售額預測
第6章 肝癌市場:附錄
圖表一覽
Abstract
Summary
GlobalData's pharmaceuticals report, "Linifanib - Analysis and Market Forecasts from 2013 to 2020" provides Linifanib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Linifanib including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Linifanib including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for Linifanib in the seven major markets
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of contents
1. Table of contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Introduction
- 2.1 Liver Cancer Market
- 2.2 Epidemiology
- 2.3 Etiology
- 2.3.1 Hepatitis B Infection
- 2.3.2 Hepatitis C Infection
- 2.3.3 Alcohol
- 2.3.4 Aflatoxin B1
- 2.3.5 Hemochromatosis
- 2.3.6 Diabetes and Obesity
- 2.3.7 Cirrhosis
- 2.4 GlobalData Report Guidance
3. Liver Cancer : Market Characterization
- 3.1 Liver Cancer Market
- 3.2 Liver Cancer Market Forecasts and CAGR
- 3.3 Drivers for the Liver Cancer Market
- 3.3.1 High Incidence
- 3.3.2 High Mortality
- 3.3.3 Large Unmet Need
4. Tumor-Node-Metastases (TNM) Classification of Liver Cancer
5. Linifanib
- 5.1 Introduction
- 5.2 Mechanism of Action
- 5.3 Clinical Studies
- 5.4 Indications of Linifanib
- 5.5 Factors Affecting Sales of Linifanib
- 5.5.1 Oral Administration
- 5.5.2 Poor Response Rate
- 5.5.3 Dual Selective Inhibition
- 5.6 Drug Risk Benefit Score
- 5.6.1 Efficacy
- 5.6.2 Safety
- 5.6.3 Compliance
- 5.6.4 Dosing Convenience
- 5.7 Intensity of Competition
- 5.8 Sales Forecasts
- 5.8.1 Target patient Pool of Linifanib
- 5.8.2 Dosing
- 5.8.3 Market Penetration
- 5.8.4 Annual Cost of Therapy
- 5.8.5 Sales Projections of Linifanib
6. Liver Cancer Market: Appendix
- 6.1 Market Definitions
- 6.2 List of Abberiviations
- 6.3 Research Methodology
- 6.3.1 Coverage
- 6.3.2 Secondary Research
- 6.3.3 Forecasting
- 6.3.4 Number of Patients Approved to take the Drug
- 6.3.5 Net Penetration of Drug
- 6.3.6 Net Annual Dosing
- 6.3.7 Annual Cost of Therapy
- 6.3.8 Primary Research
- 6.3.9 Expert Panels
- 6.4 Drug Sales Estimates Model
- 6.5 Contact Us
- 6.6 Disclaimer
- 6.7 Sources
List of Tables
- Table 1: Liver Cancer, Incidences and Mortality, 2008-2030
- Table 2: Drug Risk Benefit Score of Linifanib
- Table 3: Annual Cost of linifanib for Liver Cancer, 2010
- Table 4: Linifanib, Liver Cancer, Global, Estimated Sales ($m), 2013-2020
- Table 5: Linifanib, Liver Cancer, The US, Estimated Sales ($m), 2013-2020
- Table 6: Linifanib, Liver Cancer, The UK, Estimated Sales ($m), 2013-2020
- Table 7: Linifanib, Liver Cancer, France, Estimated Sales ($m), 2013-2020
- Table 8: Linifanib, Liver Cancer, Germany, Estimated Sales ($m), 2013-2020
- Table 9: Linifanib, Liver Cancer, Italy, Estimated Sales ($m), 2013-2020
- Table 10: Linifanib, Liver Cancer, Spain, Estimated Sales ($m), 2013-2020
- Table 11: Linifanib, Liver Cancer, Japan, Estimated Sales ($m), 2013-2020
List of Figures
- Figure 1: Fatality = [(% Distribution of Incidence) - (% Distribution of Mortality)] of Most Common Cancers
- Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 2010-2020
- Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 2008-2030
- Figure 4: Oncology, Worldwide, Incidence (in millions), 2008-2030
- Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 2008-2030
- Figure 6: Classification of Liver Cancer
- Figure 7: Clinical Trials Results, Linifanib
- Figure 8: Drug Model Diagram of Linifanib
- Figure 9: Linifanib, Liver Cancer, Global, Estimated Sales ($m), 2013-2020
- Figure 10: Linifanib, Liver Cancer, The US, Estimated Sales ($m), 2013-2020
- Figure 11: Linifanib, Liver Cancer, The UK, Estimated Sales ($m), 2013-2020
- Figure 12: Linifanib, Liver Cancer, France, Estimated Sales ($m), 2013-2020
- Figure 13: Linifanib, Liver Cancer, Germany, Estimated Sales ($m), 2013-2020
- Figure 14: Linifanib, Liver Cancer, Italy, Estimated Sales ($m), 2013-2020
- Figure 15: Linifanib, Liver Cancer, Spain, Estimated Sales ($m), 2013-2020
- Figure 16: Linifanib, Liver Cancer, Japan, Estimated Sales ($m), 2013-2020
- Figure 17: Linifanib, Liver Cancer, Global, Sales Distribution (%), 2020
- Figure 18: Drug Model Diagram
- Figure 19: Patients Approved for the Drug
|
